NGL Fine-Chem Limited — PPTs, 07-08-2025: Investor Presentation

Here is the summary of the attached file:

**1. Financial Highlights:**

NGL Fine-Chem's Q1FY26 revenue hit ₹104.19 Cr (+14.8% YoY). EBITDA sharply rebounded to ₹10.97 Cr (+73.64% QoQ), boosting margins to 10.53%. PAT of ₹9.24 Cr was flat YoY but significantly up QoQ.

**2. Strategic Initiatives & Growth Drivers:**

A key ₹160 Cr greenfield CAPEX (₹119.83 Cr invested) targets Q4FY26 completion for FY27 contributions. Diversifying into regulated markets is a strategic priority for profitability. Brownfield expansion at Macrotech is complete.

**3. Business Developments:**

Despite challenging markets, NGL achieved Q1 topline growth via higher volumes and improved cost absorption. Animal API is 90% of revenue. India (26%) and USA (6%) showed increased geographic contributions.

**4. Market Position & Competitive Advantage:**

NGL leads the Veterinary API segment, supplying major global animal healthcare firms. 95% in-house, backward-integrated manufacturing ensures cost competitiveness and quality (zero rejections in 15 years), with global regulatory approvals.

**5. Investor Implications:**

Q1FY26 results indicate operational recovery and improved margins. Extensive CAPEX offers positive growth potential, but execution timelines warrant attention. Focus on regulated markets could boost future profitability.